The role of adjuvants in vaccines for seasonal and pandemic influenza

Vaccine

Volumn 28, Issue 50, 2010, Pages 8043-8045

  Brown, Lorena E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adjuvants; Alum; Influenza vaccine; ISCOMATRIX; Lipopeptide

Indexed keywords

ALUMINUM PHOSPHATE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; ISCOMATRIX; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; INFLUENZA VACCINATION; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; CHOLESTEROL; DRUG COMBINATIONS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; PHOSPHATES; PHOSPHOLIPIDS; SAPONINS;

EID: 78650248731     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.024     Document Type: Article

References (18)

1. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New England Journal of Medicine 2006, 354(13):1343-1351.
2. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nature Reviews in Immunology 2009, 9(4):287-293.
3. Sanders M.T., Brown L.E., Deliyannis G., Pearse M.J. ISCOM-based vaccines: the second decade. Immunology and Cell Biology 2005, 83(2):119-128.
4. Maraskovsky E., Schnurr M., Wilson N.S., Robson N.C., Boyle J., Drane D. Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunology and Cell Biology 2009, 87(5):371-376.
5. Middleton D., Rockman S., Pearse M., Barr I., Lowther S., Klippel J., et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. Journal of Virology 2009, 83(15):7770-7778.
6. Muhlradt P.F., Kiess M., Meyer H., Sussmuth R., Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. Journal of Experimental Medicine 1997, 185(11):1951-1958.
7. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(43):15440-15445.
8. Lau Y.F., Deliyannis G., Zeng W., Mansell A., Jackson D.C., Brown L.E. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. International Immunology 2006, 18(12):1801-1813.
9. Schjetne K.W., Thompson K.M., Nilsen N., Flo T.H., Fleckenstein B., Iversen J.G., et al. Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. Journal of Immunology 2003, 171(1):32-36.
10. Belz G.T., Wodarz D., Diaz G., Nowak M.A., Doherty P.C. Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. Journal of Virology 2002, 76(23):12388-12393.
11. Deliyannis G., Kedzierska K., Lau Y.F., Zeng W., Turner S.J., Jackson D.C., et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. European Journal of Immunology 2006, 36(3):770-778.
12. Day E.B., Zeng W., Doherty P.C., Jackson D.C., Kedzierska K., Turner S.J. The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. Journal of Immunology 2007, 179(4):2187-2194.
13. Deliyannis G., Jackson D.C., Ede N.J., Zeng W., Hourdakis I., Sakabetis E., et al. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. Journal of Virology 2002, 76(9):4212-4221.
14. Ng W.C., Gilbertson B., Lim B., Zeng W., Jackson D.C., Brown L.E. Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cells in the control of highly virulent influenza. Influenza and Other Respiratory Viruses 2009, 3(4):177-182.
15. Brown L.E., Deliyannis G., Kedzierska K., Lau Y.F., Ng W.C., Zeng W., et al. Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cell responses in the control of seasonal and pandemic influenza. Options for the control of influenza VI 2008, 199-201. International Medical Press, Atlanta. J.M. Katz (Ed.).
16. Brown L.E., Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunology and Cell Biology 2009, 87(4):300-308.
17. Seya T., Matsumoto M. A lipoprotein family from Mycoplasma fermentans confers host immune activation through Toll-like receptor 2. International Journal of Biochem Cell Biology 2002, 34(8):901-906.
18. Dearman R.J., Cumberbatch M., Maxwell G., Basketter D.A., Kimber I. Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells. Immunology 2009, 126(4):475-484.